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Abstract
Artesunate (AS) is a clinically versatile artemisinin derivative utilized for the treatment of mild to severe malaria
infection. Given the therapeutic significance of AS and the necessity of appropriate AS dosing, substantial research
has been performed investigating the pharmacokinetics of AS and its active metabolite dihydroartemisinin (DHA).
In this article, a comprehensive review is presented of AS clinical pharmacokinetics following administration of AS
by the intravenous (IV), intramuscular (IM), oral or rectal routes. Intravenous AS is associated with high initial AS
concentrations which subsequently decline rapidly, with typical AS half-life estimates of less than 15 minutes. AS
clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively. DHA concentrations peak
within 25 minutes post-dose, and DHA is eliminated with a half-life of 30 - 60 minutes. DHA clearance and volume
average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively. Compared to IV administration, IM administration
produces lower peaks, longer half-life values, and higher volumes of distribution for AS, as well as delayed peaks
for DHA; other parameters are generally similar due to the high bioavailability, assessed by exposure to DHA,
associated with IM AS administration (> 86%). Similarly high bioavailability of DHA (> 80%) is associated with oral
administration. Following oral AS, peak AS concentrations (Cmax) are achieved within one hour, and AS is
eliminated with a half-life of 20 - 45 minutes. DHA Cmax values are observed within two hours post-dose; DHA
half-life values average 0.5 - 1.5 hours. AUC values reported for AS are often substantially lower than those
reported for DHA following oral AS administration. Rectal AS administration yields pharmacokinetic results similar
to those obtained from oral administration, with the exceptions of delayed AS Cmax and longer AS half-life. Drug
interaction studies conducted with oral AS suggest that AS does not appreciably alter the pharmacokinetics of
atovaquone/proguanil, chlorproguanil/dapsone, or sulphadoxine/pyrimethamine, and mefloquine and pyronaridine
do not alter the pharmacokinetics of DHA. Finally, there is evidence suggesting that the pharmacokinetics of AS
and/or DHA following AS administration may be altered by pregnancy and by acute malaria infection, but further
investigation would be required to define those alterations precisely.
Background
Derivatives of the naturally occurring endoperoxide anti-
malarial artemisinin form the foundation of the current
global treatment approach for Plasmodium falciparum
malaria. These derivatives, including artesunate (AS),
artemether and dihydroartemisinin, produce more pro-
found reductions in parasitaemia and more rapid symp-
tom relief than agents from any other anti-malarial
class. Of these derivatives, AS is the most therapeutically
versatile agent. As with the other derivatives, AS can be
administered orally for the treatment of uncomplicated
malaria. Specifically, artemisinin-based combination
therapies containing AS partnered with longer acting
anti-malarial agents, such as mefloquine or
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oral treatment of uncomplicated falciparum malaria [1].
Among the artemisinin derivatives, however, only AS
displays sufficient water solubility to be administered
intravenously; per the World Health Organization treat-
ment guidelines, intravenous AS is the preferred therapy
for severe malaria infection in both adult and paediatric
patients [1]. AS can also be administered intramuscu-
larly or rectally, with AS suppositories for rectal admin-
istration representing a means of initiating treatment of
severe malaria before patients are referred to distant
facilities for intravenous therapy.
Given the therapeutic significance and versatility of
AS, and the necessity of appropriate dosing to avoid
suboptimal efficacy or encouragement of resistance,
research defining the pharmacokinetics (PK) of AS, and
its active metabolite dihydroartemisinin (DHA), is of
substantial clinical relevance. The intent of this review is
to examine clinical pharmacokinetic findings of AS and
DHA following AS administration by the intravenous
(IV), intramuscular (IM), oral and rectal routes. To this
end, an extensive literature search was conducted utiliz-
ing the PubMed database and the bibliographies of iden-
tified articles in order to locate AS clinical
pharmacokinetic studies in which parameters for AS
and/or DHA are reported. The PubMed database was
searched using combinations of the following search
terms: artesunate, dihydroartemisinin, artemisinin, and
pharmacokinetics. Conference abstracts and non-English
language articles were not considered for inclusion in
the review.
To facilitate comparison of results among various stu-
dies, units for these parameters were converted, as
necessary, to a uniform scale as noted in the tables
included in this review. Additionally, individual PK ana-
lyses and population pharmacokinetic (PopPK) analyses
are described separately for each route of administra-
tion, where applicable, to enable adequate description of
the findings from each analysis method.
Sources of variation introduced by study methodology
Multiple factors complicate comparison and summation
of AS/DHA pharmacokinetic findings across multiple
studies, including differences in assay sensitivities, sam-
pling schedules, and choice of anticoagulant for blood
sample collection. Differences in sampling schedules are
of particular importance in comparisons of AS pharma-
cokinetic parameters; a relative lack of sampling points
in the early post-dose period can result in much of sub-
jects’ AS exposure being missed. With regard to choice
of anticoagulant, if fluoride-oxalate, rather than heparin,
is included as the anticoagulant in blood sample collec-
tion tubes, ex vivo plasma esterase degradation of AS to
DHA is greatly inhibited [2]. This inhibition allows for
greater preservation of a subject’s AS concentrations at
the time of blood sample collection. However, fluoride-
oxalate may also result in greater erythrocyte shrinkage
than heparin, and therefore increased plasma volume
[2]. Given these sources of variation, differences in phar-
macokinetic findings among the studies described in this
review cannot necessarily be regarded as solely related
to whatever specific demographic or clinical features
characterize the study subjects.
Artesunate and DHA protein binding
Binding of AS to human plasma proteins has been
investigated utilizing equilibrium dialysis with [
14C] arte-
sunate. AS was determined to be 75% protein bound at
plasma concentrations less than 125 ng/mL, and 62%
protein bound at higher concentrations [3]. DHA
plasma protein binding, when measured by similar
means, was determined to be 82% at plasma concentra-
tions less than 25 ng/mL and 66% at higher concentra-
tions [4]. DHA percent bound was also assessed by
ultrafiltration in patients with malaria infection (falci-
parum or vivax), Vietnamese healthy volunteers, and
Caucasian volunteers and determined to be 93%, 88%,
and 91%, respectively [5]. However, as AS and DHA are
both high extraction ratio drugs [6], any alterations in
patients’ protein binding capacity would not be expected
to produce clinically relevant changes in the clearance
of either agent.
Intravenous administration: artesunate pharmacokinetics
The pharmacokinetic results of the identified studies in
which intravenous AS PK were assessed are presented
in Tables 1 and 2[7-15]; both AS and DHA PK were
described in eight of these studies, with only DHA PK
described in the ninth [15]. In clinical settings, IV AS is
administered as a bolus injection [16]. As the identified
studies replicated this administration method, very high
AS maximum concentrations (Cmax) were observed. AS
is metabolized through esterase-catalyzed hydrolysis to
yield its active metabolite, DHA [17]; this conversion
occurs quickly following IV AS administration as indi-
c a t e db yt h er a p i dd e c l i n ei nA Sc o n c e n t r a t i o n si nt h e
early post-dose period. In six of the eight studies in
which AS PK were assessed, average AS half-life follow-
ing IV AS was determined to be less than five minutes
in at least one study cohort. In all of the studies, average
AS half-life was determined to be less than fifteen min-
utes. Finally, per the findings of Li et al [11], AS was
determined to display dose linearity following IV admin-
istration across a dosage range of 0.5 - 8 mg/kg.
Examination of the AS clearance and volume esti-
mates summarized in Table 1 indicates that the para-
meters obtained by Newton et al [13] are dissimilar
from the parameters obtained in other studies, likely
Morris et al. Malaria Journal 2011, 10:263
http://www.malariajournal.com/content/10/1/263
Page 2 of 17due to lack of sampling prior to 15 minutes post-dose;
the other summarized studies included a sampling point
at or before five minutes. The remaining seven studies
have more consistent clearance and volume estimates,
with averages ranging from 1.3 - 4.26 L/kg/hr and 0.08 -
0.44 L/kg, respectively. A majority of the estimates
range between 2 - 3 L/kg/hr for clearance and 0.1 - 0.3
L/kg for volume.
Intravenous administration: DHA pharmacokinetics
In all of identified IV AS studies, the time to maximum
concentration (Tmax) of DHA following IV AS adminis-
tration was less than 25 minutes. DHA metabolism
occurs through conjugation of DHA by the UDP-glucur-
onosyltransferase system, with UGT1A9 and UGT2B7
being the primary responsible isoforms [18]. This DHA
elimination process occurs somewhat more slowly than
the esterase-catalyzed AS elimination, with average half-
life estimates for DHA following IV AS administration
ranging from 18 minutes to 2.14 hours, with eight of
the nine studies citing average estimates for all study
cohorts of less than 65 minutes and the majority of esti-
mates falling between 30 - 60 minutes. DHA apparent
clearance (Cl/F) and volume of distribution (V/F)
averages ranged from 0.48 - 5.6 L/kg/hr and 0.55 -
2.403 L/kg, with a majority of the estimates averaging
0.5 - 1.5 L/kg/hr for clearance and 0.5 - 1.0 L/kg for
volume. As with AS, DHA displayed dose-linearity
across an IV AS dosage range of 0.5 - 8 mg/kg [11].
Intravenous administration: bioassay results
The anti-malarial bioassay method for determination of
AS/DHA plasma concentrations provides values in DHA
equivalents reflecting the contribution of both AS and
DHA present in the sample. An assessment of anti-
malarial bioactivity in patients with acute uncomplicated
falciparum malaria administered 2 mg/kg IV AS yielded
estimates for half-life, volume of distribution at steady
state (Vss), and clearance of 0.73 hours, 0.61 L/kg, and
0.83 L/kg/hr, respectively [19]. Bioassay data were also
used to compute the pharmacokinetic parameters fol-
lowing administration of 2.4 mg/kg IV AS to
Table 1 Summary of AS pharmacokinetic results following IV AS administration
Ref. Subjects & Regimen Cmax (ng/mL) Clearance
(L/kg/hr)
Volume (L/kg) Half-life
(min)
AUC
(ng*hr/mL)
[7]
Batty, Le
et al, 1998
12 Vietnamese adults with vivax malaria
120 mg IV AS over 2 min
13685†
a 3.01 0.16 2.19 876†
[9]
Binh et al,
2001
17 healthy Vietnamese volunteers; subjects randomized
into two groups, both receiving:
120 mg IV AS over 2 min
3.0; 2.2 0.19; 0.16 2.6; 3.3 846; 1269†
[10]
Ilett et al,
2002
23 Vietnamese adults with uncomplicated falciparum
malaria; subjects randomized into two groups, both
receiving:
120 mg IV AS over 2 min
16146;
16530†
2.8; 2.1 0.22 3.2 1038; 1230†
[11]
Li et al,
2009
30 healthy volunteers
0.5, 1, 2, 4, or 8 mg/kg IV AS over 2 min
4797; 6128;
19420; 36100;
83340
1.3; 18; 1.3;
1.4; 1.6†
Vss: 0.092; 0.187;
0.106; 0.109;
0.165†
7.2; 8.4;
14.4; 9.0;
12.6†
386; 593;
1595; 3038;
6994†
[12]
Nealon et
al, 2002
28 paediatric Gabonese patients with severe malaria
randomized into two groups
Group 1: 2.4 mg/kg IV AS
Group 2: 1.2 mg/kg IV AS
Group 1:
29677
a
Group 2:
15369
a
Group 1:
3.12†
a
Group 2:
4.26†
a
Group 1 Vss:
0.17†
a
Group 2 Vss:
0.44†
a
Group 1:
1.5
a
Group
2:11.5
a
Group 1:
1042†
a
Group 2:
555†
a
[13]
Newton et
al, 2006
17 adults with severe falciparum malaria in Thailand
2.4 mg/kg IV AS over 2 min
[2.1 (1.4 - 2.8 mg/kg)]
130
+†
a 64
a Vss:
15.2
a
13.2
+†
a 49.2†
a
[8]
Batty. Thu
et al, 1998
26 adult uncomplicated falciparum malaria patients in
Vietnam
120 mg IV AS over 2 min
2.33
a 0.140
a 2.73 1146†
[14]
Davis et
al, 2001
30 parasitaemic adults with falciparum malaria
Group 1: 12 with complications (120 mg IV AS over 2
min)
Group 2: 8 without complications
(120 mg IV AS over 2 min)
Group 3: 10 with moderately severe complications
(240 mg IV AS infused over 4 hours; samples taken after
infusion discontinued)
Group 1:
1.63
Group 2:
2.49
Group 3:
3.07
Group 1:
0.08
Group 2:
0.24
Group 3:
0.23
Group 1:
2.3
Group 2:
4.3
Group 3:
3.2
Values given as mean unless otherwise specified.
†Units converted to uniform scale +The authors note that Cmax is likely underestimated and half-life overestimated due to the lack of usable data from six
patients with extremely rapid AS elimination. a.Median
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reported half-life estimates for normal and thalassaemic
subjects were 1.37 and 1.95 hours, respectively, with
Tmax for bioassay activity occurring by the first sam-
pling point (15 minutes) [20]. As would be expected
given the more extended half-life of DHA, these bioas-
say results appear somewhat more reflective of the DHA
results than the AS results derived from traditional ana-
lytical methods.
Intramuscular administration: artesunate and DHA
pharmacokinetics
Tables 3 and 4[10,12,21] summarize the results of the
identified studies examining AS and DHA PK following
IM AS administration. Average estimates of the absolute
bioavailability of IM AS, as determined by DHA concen-
trations, were 86.4% [12] and 88% [10] in adult and pae-
diatric falciparum malaria patients, respectively. The
average time to maximum AS concentrations following
IM administration ranged from 7.2 - 12 minutes; aver-
age AS half-life ranged from 25.2 - 48.2 minutes. This
more extended AS half-life following IM administration
of AS presumably indicates that the AS elimination rate
was being limited by the rate of absorption from the site
of injection. Average estimates for AS apparent clear-
ance and volume of distribution ranged from 2.4 - 3.48
L/kg/hr and 1.09 - 3.98 L/kg, respectively. As would be
expected given the high bioavailability of IM AS, these
Table 2 Summary of DHA pharmacokinetic results following IV AS administration
Ref. Subjects & Regimen Cmax
(ng/mL)
Tmax
(min)
Clearance
(L/kg/hr)
Volume
(L/kg)
Half-life
(min)
AUC
(ng*hr/mL)
[7]
Batty, Le
et al,
1998
12 Vietnamese adults with vivax malaria
120 mg IV AS over 2 min
2192†
a 8
a 1.10 0.92 36.7 1845†
[9]
Binh et
al, 2001
17 healthy Vietnamese volunteers; subjects
randomized into two groups, both receiving:
120 mg IV AS over 2 min
1507;
1678†
9; 16 53; 47
[10]
Ilett et al,
2002
23 Vietnamese adults with uncomplicated
falciparum malaria; subjects randomized into two
groups, both receiving:
120 mg IV AS over 2 min
2758;
2730†
a
7; 9
a 0.64; 0.48 0.8; 0.55 59; 50 2872; 3298†
[11]
Li et al,
2009
30 healthy volunteers
0.5, 1, 2, 4, or 8 mg/kg IV AS over 2 min
428; 802;
1286; 3148;
4744
9.6; 15; 9.6;
7.2; 24†
1.3; 0.98;
1.1; 0.86;
0.82†
Vss: 1.734;
2.201; 1.860;
1.701; 2.403†
57.6; 92.4;
69.0; 82.2;
128.4†
385; 1082;
1850; 4886;
10410
[12]
Nealon
et al,
2002
28 paediatric Gabonese patients with severe
malaria randomized into two groups
Group 1: 2.4 mg/kg IV AS
Group 2: 1.2 mg/kg IV AS
Group 1:
3011†
a
Group 2:
1584†
a
Group 1:
0.5
a
Group 2:
1.4
a
Group 1:
2.16†
a
Group 2:
1.08†
a
Group 1
Vss: 0.75
a
Group 2
Vss: 0.77
a
Group 1:
20.7
a
Group 2:
32.0
a
Group 1:
923†
a
Group 2:
737†
a
[13]
Newton
et al,
2006
17 adults with severe falciparum malaria in Thailand
2.4 mg/kg IV AS over 2 min
[2.1 (1.4 - 2.8 mg/kg)]
605†
a Tmax
reached by
15 min
5.6
a Vss: 1.9
a 20.4†
a 418†
a
[8]
Batty.
Thu et al,
1998
26 adult uncomplicated falciparum malaria patients
in Vietnam
120 mg IV AS over 2 min
2648†
a 9.0
a 0.75
a 0.76 40.2 2377†
[14]
Davis et
al, 2001
30 parasitaemic adults with falciparum malaria
Group 1: 12 with complications
Group 2: 8 without complications
Group 1 & 2:
120 mg IV AS over 2 min
Group 3: 10 with moderately severe complications
(240 mg IV AS infused over 4 hours; samples taken
after infusion discontinued)
Group 1:
2417†
Group 2:
2531†
Group 3:
910 †
Group 1:
10.4
Group 2:
9.9
Group 3:
240 (end
of infusion)
Group 1:
1.09
Group 2:
0.73
Group 3:
0.73
Group 1:
0.77
Group 2:
1.01
Group 3:
0.78
Group 1:
40.0
Group 2:
64.1
Group 3:
46.2
Group 1:
2078†
Group 2:
2559†
Group 3:
5573†
Krishna
et al,
2001
[15]
34 Ghanaian children (8 months - 7 years) with
moderate falciparum malaria
Group 1 & 2: AS rectal suppository, IV AS 2.4 mg/kg
12 hr later
Group 3: 2.4 mg/kg IV AS, AS rectal suppository 12
hr later
Groups 1 &
2:
1280†
a
Group 3:
1592 †
a
Groups 1 &
2:
12†
a
Group 3:
12†
Groups 1 &
2:
1.5
a
Group 3:
1.0
a
Groups 1 & 2:
0.6
a
Group 3:
0.9
a
Groups 1 &
2:
18†
a
Group 3:
31.8†
a
Groups 1 &
2:
1166†
a
Group 3:
1706†
a
Values given as mean unless otherwise specified.
†Units converted to uniform scale a. Median
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higher than those obtained following IV AS
administration.
Maximum DHA concentrations following IM AS
administration occurred, on average, within the first 45
minutes post-dose. Average estimates for DHA half-life,
apparent clearance, and apparent volume of distribution
following IM AS ranged from 31.9 - 64 minutes, 0.73 -
2.16 L/kg/hr, and 1.1 - 1.7 L/kg, respectively; all of these
values are quite similar to those obtained following IV
AS administration.
Oral administration: artesunate pharmacokinetics
Based upon complete metabolism to DHA, AS displays
high oral bioavailability when assessed by exposure to
its active metabolite DHA. Following intravenous and
oral AS, the oral bioavailability of DHA was determined
to be 82% in healthy adults [9], 85% in adults with
uncomplicated falciparum malaria [8], and 80% in adults
with vivax malaria [7]. It should be noted, however, that
these bioavailability results may reflect both the absorp-
tion of AS, with subsequent conversion to DHA through
first-pass or systemic metabolism, as well as direct
absorption of DHA following its formation in the gut
through acid-dependent chemical hydrolysis [22].
Although physiologically plausible, the extent of such
chemical hydrolysis has not been well quantified. Fol-
lowing oral administration, AS concentrations are
detectable early, often within 15 minutes post-dose.
Peak AS concentrations also occur early, with AS Tmax
typically being detected within the first hour post-dose
(Table 5; [6,23-37]). These findings suggest that AS is
absorbed quickly and without appreciable lag.
AS half-life estimates available in the literature are
summarized in Table 6 ([28-31,35-37]), with average AS
half-life reported for any cohort in the identified studies
r a n g i n gf r o m0 . 3 6-1 . 2h o u r s .A l ls t u d i e si nw h i c hA S
half-life was determined cite AS half-life values between
2 5a n d4 0m i n u t e sf o ra tl e a s to n es t u d yc o h o r t .T h e r e
are few published estimates of AS apparent clearance
Table 3 Summary of AS pharmacokinetic results following IM AS administration
Ref. Subjects & Regimen Cmax
(ng/mL)
Tmax
(min)
Clearance
(L/kg/hr)
Volume
(L/kg)
Half-life
(min)
AUC
(ng*hr/mL)
[10]
Ilett et al,
2002
11 Vietnamese adults with uncomplicated falciparum
malaria
120 mg AS administered by intramuscular injection
884†
a 12
a 2.9 2.6 41 999†
[21]
Hien et al,
2004
9 Vietnamese adults with severe falciparum malaria
2.4 mg/kg AS administered by intramuscular injection
2195†
a 2.84
a 1.09
a 30
a 856†
a
[12]
Nealon et al,
2002
28 paediatric Gabonese patients with severe malaria
randomized into two groups
Group 1: 2.4 mg/kg IV AS, followed by 1.2 mg/kg IM AS
12 hours later
Group 2: 2.4 mg/kg IM AS, followed by 1.2 mg/kg IV AS
12 hours later
Group 1:
615†
a
Group 2:
661†
a
Group
1:
7.2
a
Group
2:
8.0
a
Group 1:
2.4†
a
Group 2:
3.48†
a
Group 1 Vss/
F: 2.07
a
Group 2 Vss/
F: 3.98
a
Group 1:
25.2
a
Group 2:
48.2
a
Group 1:
535†
a
Group 2:
544†
a
Values given as mean unless otherwise specified.
†Units converted to uniform scale a. Median
Table 4 Summary of DHA pharmacokinetic results following IM AS administration
Ref. Subjects & Regimen Cmax
(ng/mL)
Tmax
(min)
Clearance
(L/kg/hr)
Volume
(L/kg)
Half-life
(min)
AUC
(ng*hr/mL)
[10]
Ilett et al,
2002
11 Vietnamese adults with uncomplicated falciparum
malaria
120 mg AS administered by intramuscular injection
1166†
a 45
a 0.73 1.1 64 2474†
F: 88%
[21]
Hien et al,
2004
9 Vietnamese adults with severe falciparum malaria
2.4 mg/kg AS administered by intramuscular injection
870†
a 35
a 1.18
a 1.79
a 52.7
a 1496†
a
[12]
Nealon et
al, 2002
28 paediatric Gabonese patients with severe malaria
randomized into two groups
Group 1: 2.4 mg/kg IV AS, followed by 1.2 mg/kg IM
AS 12 hours later
Group 2: 2.4 mg/kg IM AS, followed by 1.2 mg/kg IV
AS 12 hours later
Group 1:
341
a
Group 2:
626
a
Group
1:
25.9
a
Group
2:
40.5
a
Group 1:
2.16†
a
Group 2:
1.5†
a
Group 1:
Vc/F: 1.2
a
Vss/F:
1.32
a
Group 2:
Vc/F: 1.2
a
Vss/F:
1.28
a
Group 1:
31.9
a
Group 2:
40.2
a
Group 1:
396†
a
Group 2:
1123†
a
Combined group
F: 86.37%
a
Values given as mean unless otherwise specified.
†Units converted to uniform scale a. Median
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administration. Teja-Isavadharm et al [35] determined
mean AS CL/F and V/F to be 20.6 L/kg/hr and 14.8 L/
kg, respectively, in six healthy adult subjects. Karbwang
et al [31] determined average AS CL/F to be 19.2 L/kg/
hr in 11 Thai adults during the acute phase of uncom-
plicated malaria infection and 9.6 L/kg/hr during the
convalescent phase. Median AS V/F was 6.8 L/kg during
both phases of infection. Finally, in paediatric Gabonese
patients with acute falciparum malaria, estimates for
average AS CL/F and V/F were 25 - 30 L/kg/hr and 25
- 41 L/kg, respectively [36].
Given that AS is a high extraction ratio drug, the sub-
stantial difference in magnitude of these AS apparent
clearance and volume estimates for oral administration,
as compared to IV or IM administration, most likely
Table 5 Artesunate Tmax values obtained following oral artesunate administration
Ref. Subjects Regimen Tmax (hours)
[23] 15 healthy Cambodian male adults 4 mg/kg AS once with mefloquine 0.75
a
[6] 8 healthy adults in Australia 150 mg AS once 0.65 (n = 6)
a
[24] 20 healthy adult males in Australia 200 mg/day × 3 days alone (Period 1); repeated
with mefloquine after washout (Period 2)
Period 1/Day 1:
0.6
b
Period 1/Day 3:
0.6
b
Period 2/Day1:
0.5
b
Period 2/Day 3:
0.6
b
[25] 6 healthy adults in Geneva 200 mg AS once 0.25 (5/6 subjects)
0.5 (1/6 subjects)
[26] 23 healthy Malaysian adults 200 mg AS once with amodiaquine as fixed or
non-fixed product
Fixed:0.26
Non-fixed:0.53
[27] 13 healthy adults in Africa Mean dose: 4.26 mg/kg with (ACT) or without
(AS only) amodiaquine as single dose
AS only: 0.62
ACT: 0.86
[28] 8 healthy male Thai adults 300 mg AS (Guilin or Arenco formulation) Guilin: 0.25
a
Arenco: 0.31
a
[29] 10 healthy male Vietnamese adults 200 mg AS once daily × 5 days Day 1: 0.8
a
Day 5: 0.8
a
[30] 12 healthy male Malaysian adults 200 mg AS once 0.66 ± 0.34
[31] 11 male Thai adults with uncomplicated falciparum malaria 200 mg AS once, followed by 100 mg 12 hours
later, then 100 mg once daily for another 4 days
Acute: 0.5
a
Convalescence:1.0
a
[32] 43 adults with uncomplicated falciparum malaria in Thailand AS+mefloquine as fixed (200 mg AS) or
nonfixed (4 mg/kg AS) combination
Fixed:0.833 (n =
19)
Nonfixed:0.925 (n
= 23)
[33] 13 male and female adult patients in the DRC with acute
uncomplicated falciparum malaria
200 mg AS once daily × 3 days with
amodiaquine
1.4 (n = 10)
[34] 86 acute uncomplicated falciparum malaria patients from Malawi and
Gambia
1, 2, or 4 mg/kg AS with chlorproguanil and
dapsone once daily × 3 days
1 mg/kg: 1.08
a
2 mg/kg: 0.55
a
4 mg/kg: 1.03
a
[35] 6 male Thai adults with uncomplicated falciparum malaria and 6 healthy
male adults
100 mg AS once Healthy: 0.71
Patients: not
determined
[36] 57 children (2-14 years) with uncomplicated falciparum malaria in
Gabon
AS dose (mg/kg/day) with pyronaridine
Group A:2.1(1.4-2.4)
Group B:3.3(2.4 - 3.9)
Group C:4.8(3.0 - 6.1)
Group D: 3.8(3.0-4.3)
Group A:0.6
Group B:0.7
Group C:1.0
Group D:0.5
[37] 40 children and adults with uncomplicated falciparum malaria in Pailin,
Cambodia and 40 adults with uncomplicated falciparum malaria in
Wang Pha, Thailand
At each site:
Group 1: AS monotherapy: 2 mg/kg/day × 7
days
Group 2: AS 4 mg/kg/day × 3 days +
mefloquine
Thailand:
Group 1: 0.38
a
Group 2: 0.50
a
Cambodia:
Group 1:0.50
a
Group 2: 1.00
a
Values given as mean unless otherwise specified.
a. Median b. Geometric mean
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conversion of AS to DHA during first-pass metabolism.
Oral administration: DHA pharmacokinetics
For studies defining both AS and DHA PK following
oral AS administration, DHA Cmax exceeds AS Cmax,
and DHA AUC exceeds AS AUC. Literature results
exemplifying this relationship between AS and DHA
pharmacokinetic exposure are summarized in Table 7
[6,26-30,32,34,35,37-39]. In many of these studies, DHA
AUC exceeds AS AUC by more than 10-fold, when con-
sidered on either a nmol*hr/mL or ng*hr/mL basis. It is
in part due to this disparity in exposure that AS is often
considered essentially a pro-drug for DHA following
oral AS administration. The maximum concentration
for DHA typically occurs within two hours post-dose.
DHA is eliminated more slowly than AS following oral
AS administration. DHA half-life was determined to be
longer than AS half-life for all studies in which both
parameters were assessed. For the studies in which
DHA half-life was estimable (Table 8; [7-9,23-32,34-43]),
the average DHA half-life ranged from 0.49 hours to
3.08 hours, with almost half of the half-life estimates
being less than one hour and most of the remaining
estimates being between 1-2 hours. Overall, most of the
half-life estimates fell between 0.5 - 1.5 hours.
DHA CL/F and V/F estimates obtained following oral
AS administration are limited. Teja-Isavadharm et al
[35] determined DHA CL/F to be 3.35 L/kg/hr in six
healthy adults and 1.01 L/kg/hr in six parasitaemic
adults. DHA apparent volume of distribution values
were 4.14 L/kg and 1.55 L/kg in healthy subjects and
malaria patients, respectively. In Gabonese children with
malaria, average DHA CL/F and V/F averaged 2.3 - 2.7
L/kg/hr and 1.6 - 4.2 L/kg, respectively [36]. Orrell et al
[27], Davis et al [24], and Zhang et al [41] computed
DHA CL/F, but did not provide values adjusted for
body weight. Adjusting CL/F using the average body
Table 6 Artesunate half-life values following oral artesunate administration
Ref. Subjects Artesunate regimen Artesunate
half-life
(hours)
[29] 10 healthy male Vietnamese adults 200 mg once daily × 5 days Day 1: 0.43
a
Day 5: 0.50
a
[30] 12 healthy male Malaysian adults 200 mg single dose 0.49
[28] 8 healthy male Thai adults 300 mg AS (Guilin or Arenco formulation) Guilin:0.53
Arenco:0.57
[26] 23 healthy Malaysian adults 200 mg AS + amodiaquine as fixed or non-
fixed product
Fixed:0.63
Non-fixed:0.76
[34] 86 acute uncomplicated falciparum malaria patients from Malawi and
Gambia
1, 2, or 4 mg/kg AS + chlorproguanil and
dapsone once daily × 3 days
1 mg/kg:
0.515
b
2 mg/kg:
0.478
b
4 mg/kg:
0.467
b
[31] 11 male Thai adults with uncomplicated falciparum malaria 200 mg AS once, followed by 100 mg 12
hours later, then 100 mg once daily × 4 days
Acute: 0.36
a
Convalescence:
0.54
a
[35] 6 male Thai adults with uncomplicated falciparum malaria and 6 healthy
male adults
100 mg AS once Healthy: 0.41
Patients: not
determined
[36] 57 children (2-14 years) with uncomplicated falciparum malaria in Gabon AS dose (mg/kg) with pyronaridine
Group A:2.1(1.4-2.4)
Group B:3.3(2.4 - 3.9)
Group C:4.8(3.0 - 6.1)
Group D: 3.8(3.0-4.3)
Group A: 0.8 (n
= 12)
Group B:1.1 (n
= 12)
Group C:0.5 (n
= 10)
Group D:1.2 (n
= 13)
[37] 40 children and adults with uncomplicated falciparum malaria in Pailin,
Cambodia and 40 adults with uncomplicated falciparum malaria in Wang
Pha, Thailand
At each site:
Group 1: AS monotherapy: 2 mg/kg/day × 7
days
Group 2: AS 4 mg/kg/day × 3 days +
mefloquine
Thailand:
Group 1: 0.37
a
Group 2: 0.58
a
Cambodia:
Group 1: 0.29
a
Group 2: 0.29
a
Value given as mean unless otherwise specified.
a. Median b. Geometric mean
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Page 7 of 17Table 7 Artesunate and DHA AUC and Cmax values following oral artesunate administration
Ref. Subjects Oral AS regimen AUC
(ng*hr/mL)
Cmax (ng/mL)
[29] 10 healthy male Vietnamese adults 200 mg once daily × 5 days AS
a
Day 1: 67
Day 5: 60
AS
a
Day 1:67
Day 5: 58
DHA
a
Day 1:1158
Day 5:1300
DHA
Pooled:654
[30] 12 healthy male Malaysian adults 200 mg AS once AS
119
AS
256.3
DHA
AUC0-t:1331
DHA
873.7
[27] 13 healthy adults in Africa Mean dose: 4.26 mg/kg with (ACT) or without
(AS only) amodiaquine single dose
AS
AS only: 206.4
ACT: 183.3
AS
AS only: 231.8
ACT: 141.6
DHA
AS only:
2044.4
ACT: 1410.5
DHA
AS only: 844.5
ACT: 446.2
[28] 8 healthy male Thai adults 300 mg AS
(Guilin and Arenco formulations)
AS
Guilin: 406
Arenco: 190.8
AS
Guilin: 397
Arenco: 194
DHA
Guilin: 1630
Arenco: 2600
DHA
Guilin: 500
Arenco:928
[6] 8 healthy adults in Australia 150 mg once AS
AUC0-6 hr:154
(n = 6)
AS
a
111 (n = 6)
DHA
AUC0-6 hr: 824
DHA
a
546
[26] 23 healthy Malaysian adults 200 mg once with amodiaquine as fixed or
non-fixed product
AS†
Fixed: 391.1
Non-fixed:
213.2
AS†
Fixed: 333
Non-fixed: 444
DHA†
Fixed: 1468.9
Non-fixed:
1656.0
DHA†
Fixed: 609.8
Non-fixed:874.5
[34] 86 acute uncomplicated falciparum malaria patients from
Malawi and Gambia
1, 2, or 4 mg/kg AS with chlorproguanil and
dapsone once daily × 3 days
AS
b
1 mg/kg: 64.6
(n = 16)
2 mg/kg:151
(n = 19)
4 mg/kg: 400
(n = 23)
AS
b
1 mg/kg: 48.9
2 mg/kg: 106
4 mg/kg: 224
DHA
b
1 mg/kg: 538
(n = 24)
2 mg/kg: 1445
(n = 29)
4 mg/kg: 383
(n = 23)
DHA
b
1 mg/kg: 228
2 mg/kg: 581
4 mg/kg: 1414
[39] 21 children (5 - 13 years) with uncomplicated malaria in
Uganda
4 mg/kg once daily with amodiaquine × 3
days
AS
113 (data
pooled from
all subjects)
AS 51 (data
pooled from all
subjects)
DHA
a
1404
DHA
a
473
[32] 43 adults with uncomplicated falciparum malaria in Thailand 200 mg/day for fixed dose AS-mefloquine
tablet (n = 20) or 4 mg/kg/day as nonfixed (n
= 23) AS-mefloquine
AS
AUC0-t:
Fixed:310
(n = 19)
Nonfixed: 419
(n = 21)
AS
Fixed:255
(n = 19)
Nonfixed:451
(n = 23)
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Page 8 of 17weight in these studies yields apparent clearance esti-
mates of 2.2 L/kg/hr (AS alone) and 2.7 L/kg/hr (with
amodiaquine) for Orrell et al [27], 1.4 - 1.7 L/kg/hr for
Davis et al [24], and 1.8 L/kg/hr for Zhang et al [41].
Adjusted DHA V/F values ranged from 1.6 - 2.6 L/kg
[24].
Oral administration: bioassay results
As was previously observed for IV bioassay studies, PK
parameters derived from bioassay data obtained follow-
ing oral AS administration appear to more closely
resemble DHA rather than AS parameters. For example,
in the four identified studies including bioassay data fol-
lowing oral AS administration, the average Tmax for
bioactivity ranged from 0.75 - 1.7 hours and average
half-life from 0.71 - 1.17 hours [19,44-46].
Oral administration: population pharmacokinetic analyses
Four population pharmacokinetic analyses describing AS
and/or DHA PK following oral AS administration were
identified, including two conducted with data from preg-
nant women (described under Artesunate and DHA
pharmacokinetics in pregnant women, below), as well as
analyses conducted using data from healthy volunteers
and from paediatric malaria patients. Specifically, Tan et
al [47] modelled the PK of AS and DHA simultaneously
utilizing extensive sampling data from 91 healthy Kor-
ean adults administered oral AS. The data were fit to a
Table 7 Artesunate and DHA AUC and Cmax values following oral artesunate administration (Continued)
DHA
AUC0-t:
Fixed:3027
Nonfixed:
3633
DHA
Fixed:1234
Nonfixed:2043
[35] 6 male Thai adults with uncomplicated falciparum malaria
and 6 healthy male adults
100 mg AS once AS
AUC0-12 hr
Healthy: 97
Patients: not
determined
AS
Healthy: 114
Patients: not
determined
DHA
AUC0-12 hr
Healthy: 501
Patients: 1144
DHA
Healthy: 339
Patients: 554
[36] 57 children (2-14 years) with uncomplicated falciparum
malaria in Gabon
AS dose (mg/kg)
Group A:2.1(1.4-2.4)
Group B:3.3(2.4 - 3.9)
Group C:4.8(3.0 - 6.1)
Group D: 3.8(3.0-4.3)
AS
Group A: 104
(n = 12)
Group B: 154
(n = 12)
Group C:232
(n = 10)
Group D: 179
(n = 13)
AS
Group A: 93
Group B:154
Group C: 287
Group D: 171
Administered with pyronaridine DHA
Group A: 1055
Group B: 1989
Group C: 2961
Group D: 2245
DHA
Group A:479
Group B: 940
Group C:1186
Group D:792
[37] 40 children and adults with uncomplicated falciparum
malaria in Pailin, Cambodia and 40 adults with
uncomplicated falciparum malaria in Wang Pha, Thailand
At each site:
Group 1: AS monotherapy: 2 mg/kg/day × 7
days
Group 2: AS 4 mg/kg/day × 3 days +
mefloquine
AS†
a
AUC0-24 hr
Thailand:
Group 1: 128
Group 2: 237
Cambodia:
Group 1: 173
Group 2: 338
AS†
a
Thailand:
Group 1: 171
Group 2: 200
Cambodia:
Group 1: 270
Group 2: 316
DHA†
a
AUC0-24 hr
Thailand:
Group 1: 1308
Group 2: 2957
Cambodia:
Group 1: 1382
Group 2: 4123
DHA†
a
Thailand:
Group 1: 859
Group 2: 1191
Cambodia:
Group 1: 802
Group 2: 1590
Values given as mean unless otherwise specified.
†Units converted to uniform scale a. Median b. Geometric mean
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Page 9 of 17Table 8 DHA half-life values obtained following artesunate administration
Ref. Subjects Artesunate regimen DHA half-life
(hours)
[29] 10 healthy male Vietnamese adults 200 mg once daily × 5 days 0.87 (from
pooled data)
[30] 12 healthy male Malaysian adults 200 mg single dose 0.49
[40] 20 male and female healthy Thai adults 4 mg/kg once 0.74
a
[27] 13 healthy adults in Africa Mean dose: 4.26 mg/kg with (ACT) or without (AS
only) amodiaquine single dose
AS only:1.46
ACT: 3.08
[28] 8 healthy male Thai adults 300 mg AS (Guilin or Arenco formulation) Guilin: 1.77
Arenco:1.73
[41] 10 healthy Vietnamese males 100 mg AS once Half-life: 0.55
b
[25] 6 healthy adults in Geneva 200 mg AS once 0.65
[26] 23 healthy Malaysian adults 200 mg once with amodiaquine as fixed or non-
fixed product
Fixed:1.68
Non-fixed:1.42
[24] 20 healthy adult males in Australia 200 mg/day × 3 days alone (Period 1); repeated
with mefloquine after washout (Period 2)
Period 1/Day 1:
1.14
Period 1/Day 3:
1.14
Period 2/Day 1:
1.02
Period 2/Day 3:
1.09
[23] 15 healthy Cambodian male adults 4 mg/kg once with mefloquine 1.30
b
[42] 12 healthy adults 200 mg once 0.68
[34] 86 acute uncomplicated falciparum malaria patients from Malawi and
Gambia
1, 2, or 4 mg/kg AS with chlorproguanil and
dapsone once daily × 3 days
1 mg/kg: 0.779
b
2 mg/kg: 0.917
b
4 mg/kg: 1.09
b
[7] 12 Vietnamese adult male vivax malaria patients 100 mg single dose 0.67 (n = 11)
[8] 26 Vietnamese adult patients with uncomplicated falciparum malaria 100 mg single dose 0.66 (n = 16)
[39] 21 children (5 - 13 years) with uncomplicated malaria in Uganda 4 mg/kg once daily with amodiaquine × 3 days 1.3
a
[38] 24 children with uncomplicated falciparum malaria in Gabon 4 mg/kg once daily for 3 days in one of two
formulations (blister pack and fixed dose) of AS/
mefloquine
Fixed dose: 0.9
(n = 9)
a
Blister pack: 1.0
(n = 11)
a
[32] 43 adults with uncomplicated falciparum malaria in Thailand 200 mg/day for fixed dose AS-mefloquine tablet or
4 mg/kg/day as nonfixed AS-mefloquine
Fixed: 1.1 (n =
14)
Nonfixed: 0.8 (n
= 18)
[31] 11 male Thai adults with uncomplicated falciparum malaria 200 mg AS once, followed by 100 mg 12 hours
later, then 100 mg once daily × 4 days
Acute: 0.64
a
Convalescence:
0.66
a
[43] 24 pregnant Karen women in the 2
nd and 3
rd trimesters with
uncomplicated falciparum malaria
4 mg/kg once daily × 3 days with atovaquone plus
proguanil
Half-life: 1.0 (n =
13)
a
PopPK half-life
estimate: 1.81 hr
[35] 6 male Thai adults with uncomplicated falciparum malaria and 6
healthy male adults
100 mg AS once Healthy: 0.85
Patients: 1.06
[9] 8 Vietnamese adults with uncomplicated falciparum malaria and 10
healthy Vietnamese adults
150 mg once Healthy: 0.77
Patients: 0.88
[53] 26 2
nd and 3
rd trimester pregnant women with asymptomatic
falciparum parasitaemia, the same women postpartum, and 25 non-
pregnant asymptomatic, parasitaemic controls
200 mg once Pregnant: 1.28
a
Postpartum:1.63
a
Controls: 1.41
a
[36] 57 children (2-14 years) with uncomplicated falciparum malaria in
Gabon
AS dose (mg/kg)
Group A:2.1(1.4-2.4)
Group B:3.3(2.4 - 3.9)
Group C:4.8(3.0 - 6.1)
Group D: 3.8(3.0-4.3)
Administered with pyronaridine
Group A:1.0
Group B: 0.9
Group C: 1.2
Group D:1.2
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Page 10 of 17parent-metabolite model with first-order AS absorption, a
one-compartment model for AS and a two-compartment
model for DHA. Adjusting for the median weight of the
study population (61.5 kg), the final estimates for AS CL/F
and V/F were 19 L/kg/hr and 20 L/kg, respectively. Simi-
larly adjusting for median weight, DHA central clearance
and central volume of distribution were 1.52 L/kg/hr and
1.58 L/kg, respectively, with weight as a statistically signifi-
cant covariate on DHA apparent clearance. The only other
significant covariate-parameter relationship identified in
the model was the effect of food intake on the AS absorp-
tion rate constant, with a reduction in absorption rate of
84% associated with administration of AS with a high fat,
high calorie meal. Inter-individual variability was esti-
mated on five of the modelled parameters, with the high-
est inter-individual variability observed for Ka (%CV =
112%) and AS V/F (%CV = 57.4%).
Stepniewska et al [48] described the PopPK of DHA
following oral AS administration in children (6 months
- 5 years) with uncomplicated falciparum malaria. AS
and DHA pharmacokinetic data were obtained from 70
children who received AS and amodiaquine, but only
DHA data could be modelled. Samples were collected
once in the first dosing interval and once in the third
dosing interval. The authors modelled DHA data using
a one-compartment model with first-order input. They
estimated DHA CL/F as 0.636 L/kg/hr for the first dos-
ing period, with a substantial additive increase of 0.760
L/kg/hr being associated with the third dosing period.
The authors speculated that this modelled increase in
clearance reflected pharmacokinetic changes related to
resolution of acute illness. DHA apparent volume of dis-
tribution, which was not modelled as varying between
dosing periods, was estimated as 2.285 L/kg, with age
modelled as a covariate on volume. The authors noted
that either age or weight explained a significant portion
of the variability on volume, but that the two covariates
were not independent. Inter-individual variability was
modelled on DHA apparent volume of distribution (%
CV = 47%), but no other parameter.
Rectal administration: AS and DHA pharmacokinetics
The bioavailability of rectally administered AS, as
assessed by exposure to DHA, in paediatric patients
with moderately severe malaria was estimated to be 23%
in patients administered a dose of 20 mg/kg and 58% in
patients administered 10 mg/kg [15]. In one rectal-oral
crossover study in healthy volunteers, the mean bioavail-
ability of rectal AS relative to oral AS, as assessed by
exposure to DHA, was 54.9% [42]. However, in a study
of similar design, no statistically significant differences
in DHA AUC0-t following oral and rectal AS administra-
tion were observed, although AS AUC was significantly
larger and DHA Cmax significantly smaller following
rectal, as compared to oral, administration [30]. The
inconsistent findings of these two studies may relate to
the difficulty of defining a sampling schedule able to
optimally capture the unique concentration-time profiles
associated with different routes of administration.
Tables 9 and 10[15,30,42,49,50] summarize the PK
findings of the identified rectal AS administration stu-
dies. Tmax for AS following rectal administration
occurred on average between 0.58 - 1.43 hours. AS half-
life was estimated in only two studies, with half-life esti-
mates of 0.9 - 0.95 hours. These longer half-life esti-
mates may reflect absorption rate-limited elimination of
AS. Following rectal administration of AS, DHA concen-
trations peaked between 1.13 - 2.0 hours, and DHA was
eliminated with a half-life averaging 0.79 - 1.8 hours.
Only one non-PopPK study [15] reported estimates of
DHA apparent clearance and volume following rectal
AS; those values were 2.6 - 3.9 L/kg/hr and 4.4 - 5.9 L/
kg, respectively. As would be expected given that rectal
AS administration avoids first-pass metabolism, the dis-
crepancy in AS and DHA AUC values is not as striking
with rectal, as compared with oral, administration of AS.
Rectal administration: population pharmacokinetic
analyses
Two population pharmacokinetic analyses of data
obtained following rectal AS administration were identi-
fied. Simpson et al [51] described the population phar-
macokinetics of DHA following rectal AS administration
to adult and paediatric patients with moderately severe
falciparum malaria. Patients were administered a single
dose of 10 mg/kg AS with follow-up treatment adminis-
tered orally. AS concentrations could not be successfully
modelled. DHA concentrations (424 levels) obtained
Table 8 DHA half-life values obtained following artesunate administration (Continued)
[37] 40 children and adults with uncomplicated falciparum malaria in Pailin,
Cambodia and 40 adults with uncomplicated falciparum malaria in
Wang Pha, Thailand
At each site:
Group 1: AS monotherapy: 2 mg/kg/day × 7 days
Group 2: AS 4 mg/kg/day × 3 days + mefloquine
Thailand:
Group 1: 0.71
a
Group 2: 0.85
a
Cambodia:
Group 1: 0.84
a
Group 2: 0.77
a
Estimates from PopPK studies are described in the text. Values given as mean unless otherwise specified.
a. Median b. Geometric mean
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Page 11 of 17from 164 patients were fit to a one-compartment model
with fixed, lagged, first-order input (DHA appearance
rate: 0.2/hr; lag: 0.14 hr). Gender and weight were iden-
tified as important covariates in the model, with DHA
CL/F of 3.17 L/kg/hr for males and 2.03 L/kg/hr for
females. DHA V/F was estimated as increasing from
1.81 L/kg for a 15 kg subject to 6.34 L/kg for a 70 kg
subject. Estimated inter-individual variability was 62%
for CL/F and 75% for V/F.
Karunajeewa et al [52] conducted population pharma-
cokinetic analysis of AS and DHA data following admin-
istration of 10 - 15 mg/kg rectal AS (2 doses, 12 hours
apart) to 47 paediatric uncomplicated falciparum or
vivax malaria patients in Papua New Guinea. AS data
and DHA data were each fit to a one-compartment
model; first-order AS absorption was modelled. Due to
identifiability concerns, the volume of distribution esti-
mates for AS and DHA were set equal (41.8 L). Weight
was an influential covariate on volume. The AS CL/F
(mean ± SD) was determined to be 121.2 ± 35.4 L/hr
and DHA CL/F to be 44.9 ± 13.0 L/hr. Average AS and
DHA half-life estimates were 0.27 and 0.71 hours,
respectively. The absorption half-life was estimated as
2.3 hours. The model included a bioavailability term for
the second dose relative to the first dose (72%). The
authors conjectured that higher core body temperature
when the first dose was administered may have resulted
in enhanced rectal blood flow and, therefore, absorption.
Table 9 Summary of AS pharmacokinetic results following rectal AS administration
Ref. Subjects & Regimen Cmax
(ng/mL)
Tmax (hours) Half-life (hours) AUC
(ng*hr/mL)
[49]
Sirivichay et al, 2007
16 paediatric patients with uncomplicated falciparum malaria
10 mg/kg (n = 7) or 20 mg/kg (n = 9) AS as rectal suppositories
507; 561†
a 0.8; 1.0
a 0.9; 0.9
a 692; 1076†
a
[50]
Halpaap et al, 1998
12 paediatric patients with uncomplicated falciparum malaria
50 mg AS as rectal suppository
[0.86 - 2.55 mg/kg AS]
90† 0.58
[30]
Navaratnam et al, 1998
12 healthy Malaysian adults
200 mg AS as rectal suppository
448.5 1.43 0.95 796
Estimates from PopPK studies are described in the text. Values given as mean unless otherwise specified.
†Units converted to uniform scale a. Median
Table 10 Summary of DHA pharmacokinetic results following rectal AS administration
Ref. Subjects & Regimen Cmax
(ng/mL)
Tmax
(hours)
Clearance
(L/kg/hr)
Volume
(L/kg)
Half-life
(hours)
AUC
(ng*hr/mL)
[49]
Sirivichay et al,
2007
16 paediatric patients with uncomplicated falciparum
malaria
10 mg/kg (n = 7) or 20 mg/kg (n = 9) AS as rectal
suppositories
898;
1535†
a
1.5; 2.0
a 1.3; 1.8
a 2403;
5633†
a
[50]
Halpaap et al,
1998
12 paediatric patients with uncomplicated falciparum
malaria
50 mg AS as rectal suppository
[0.86 - 2.55 mg/kg AS]
180† 1.13
[42]
Awad et al,
2004
12 healthy Sudanese adults
200 mg AS as rectal suppository
219.1† 1.95 1.21 1185.17
[30]
Navaratnam et
al, 1998
12 healthy Malaysian adults
200 mg AS as rectal suppository
385.6† 1.80 AUC0-t
965
Krishna et al,
2001
[15]
34 Ghanaian children (8 months - 7 years) with
moderate falciparum malaria
Group 1: AS 10 mg/kg as rectal suppository, IV AS 2.4
mg/kg 12 hr later
Group 2: AS 20 mg/kg AS as rectal suppository, IV AS
2.4 mg/kg 12 hr later
Group 3: 2.4 mg/kg IV AS, 20 mg/kg AS as rectal
suppository 12 hr later
Group 1:
682†
a
Group 2 &
3:
881†
a
Group 1:
1.7
a
Tlag:
0.63
a
Group 2
&3 :
1.8
a
Tlag:
0.37
a
Group 1:
2.6
Group 2 &
3:
3.9
Group 1:
4.4
a
Group 2 &
3:
5.9
a
Group 1:
0.79
a
Group 2 &
3:
0.85
a
Group 1:
2787 †
a
Group 2 &
3:
3753†
a
Estimates from PopPK studies are described in the text. Values given as mean unless otherwise specified
†Units converted to uniform scale a. Median
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Page 12 of 17Artesunate and DHA pharmacokinetics in paediatric
patients
The two previously described population pharmacoki-
netic models describing AS/DHA PK following rectal
AS administration were conducted using data from a
mixed adult and paediatric population [51] or an exclu-
sively paediatric population [52]; in both of these ana-
lyses, weight represented a significant covariate on DHA
apparent volume of distribution. In the PopPK analysis
of DHA following oral AS administration to young chil-
dren, Stepniewska et al [48], determined that either
weight or age could explain a significant portion of the
between subject variability in DHA volume of distribu-
tion. These findings suggest that weight, or a highly cor-
related covariates such as age, is an important predictor
variable for DHA PK in paediatric patients. The practice
of utilizing AS regimens targeted to a mg/kg dosage
range should somewhat aid in minimizing weight-based
variability in exposure. However, further study would be
required in the paediatric population to assess if patient
age is an important source of variability beyond that
explained by body weight alone. Such study would opti-
mally focus on infants and very young children since the
most marked differences in drug metabolism and other
physiologic processes would be expected in this patient
population.
Artesunate and DHA pharmacokinetics in pregnant
women
Two pharmacokinetic trials have been conducted to
characterize AS/DHA pharmacokinetic changes that
may be associated with the physiologic changes of preg-
nancy. McGready et al [43] modelled the PK of DHA
following oral administration of AS to 2
nd and 3
rd trime-
ster pregnant women with acute uncomplicated malaria.
Population modelling yielded DHA CL/F and V/F esti-
mates of 1.77 L/kg/hr and 4.63 L/kg. Non-compartmen-
tal analysis of their data yielded estimates of 4.0 L/kg/hr
for CL/F and 3.4 L/kg for V/F. The authors noted that
exposure to DHA following oral AS administration to
the pregnant women in the study was substantially
lower than that observed in non-pregnant subjects in
previous studies.
Onyamboko et al [53] examined the PK of DHA fol-
lowing the oral administration of 200 mg AS to 26 2
nd
and 3
rd trimester pregnant women with asymptomatic
falciparum parasitaemia, the same women 3 months
post-partum, and 25 matched asymptomatic parasitae-
mic female controls in the Democratic Republic of
Congo. The median DHA CL/F was 1.39 L/kg/hr, 1.26
L/kg/hr, and 1.07 L/kg/hr for pregnant, post-partum,
and non-pregnant control subjects, respectively. Median
DHA V/F was 2.84 L/kg for pregnant, 3.00 L/kg for
post-partum, and 2.45 L/kg for non-pregnant control
subjects. DHA AUC was significantly different (geo-
metric mean ratio: 0.68, 90% CI: 0.57 - 0.81) for the
pregnant as compared to control subjects; however,
DHA AUC values for pregnant women and the same
women at three months post-partum were relatively
similar. A population pharmacokinetic analysis [54] of
t h eA Sa n dD H Ad a t af r o mp r e g n a n ta n dc o n t r o l
w o m e ni nt h eO n y a m b o k oet al study modelled the
data using mixed-order absorption with a one-compart-
ment model for AS and a one-compartment model for
DHA; in that analysis, pregnancy was associated with a
significant increase in DHA CL/F, as well as a trend
towards increased volume of distribution.
Artemisinin resistance in Plasmodium falciparum malaria
The recent emergence in western Cambodia of P. falci-
parum with reduced susceptibility to artemisinin deriva-
tives has been the source of substantial concern;
questions regarding the relationship between the phar-
macokinetics of these derivatives and the observed
delayed parasite clearance times have been posed. Don-
dorp et al [37] assessed the efficacy of two regimens of
AS for uncomplicated falciparum malaria at a site in
western Cambodia, where reduced susceptibility was
expected, and another in northwestern Thailand, where
substantially reduced susceptibility was not anticipated.
These regimens consisted of 2 mg/kg/day oral AS
monotherapy × 7 days or 4 mg/kg/day oral AS × 3 days
followed by two doses of mefloquine. As expected,
patients in Cambodia displayed significantly longer para-
site clearance times as compared to patients in Thailand.
However, no apparent clinically relevant differences in
AS and DHA pharmacokinetics were observed between
the two study sites. Additionally, no relationship
between measures of AS or DHA exposure and parasite
clearance time was observed. These results suggest that
the observed reduced artemisinin susceptibility of P. fal-
ciparum in western Cambodia is not highly sensitive to
PK parameters for AS and DHA within the 2 - 4 mg/
kg/day AS dosage range.
Effect of infection status on artesunate and DHA
pharmacokinetics
Multiple studies have attempted to investigate and char-
acterize any changes in AS and DHA PK associated
with malaria infection. Two of the studies described
above, conducted by Stepniewska et al [48] and Karb-
wang et al [31], determined that the PK of orally admi-
nistered AS may differ in the acute stage of infection as
compared to the convalescent stage. Stepniewska et al
[48] determined that DHA clearance was substantially
lower on the first day of treatment as compared to the
third day. Karbwang et al [31] determined that DHA
Cmax was significantly decreased, and AUC not
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compared to the fifth day. On the first day of treatment,
higher AS clearance was also reported. Newton et al
[19] used bioassay data to investigate the anti-malarial
activity in patients with falciparum malaria during the
patients’ acute and convalescent phases. The analysis
indicated that anti-malarial activity AUC and Cmax
were two-fold higher in the acute phase as compared to
the convalescent phase for subjects administered the
same dose of oral AS. Correspondingly, apparent clear-
ance and volume of distribution of anti-malarial activity
were significantly smaller in the acute phase of infection.
Although these three studies do not fully align regarding
the effect of disease resolution on AS/DHA PK, perhaps
due to the use of differing populations, sampling time
points, and time course of sampling, taken together
these studies do suggest that some alteration in PK may
occur over the course of treatment. It should be noted
that changes over the course of treatment are likely not
due to time-dependency of AS or DHA PK, as has been
observed with various other artemisinin derivatives; fol-
lowing oral administration of AS over a typical treat-
ment course, time-dependent kinetics are not apparent
[55].
A direct comparison of healthy and parasitaemic sub-
jects was conducted by Teja-Isavadharm et al [35], who
studied the PK of DHA following oral AS administration
to six healthy adults and six adult falciparum malaria
patients. The investigators determined that AUC and
Cmax of DHA were significantly higher in subjects with
malaria as compared to healthy subjects. Binh et al [9]
obtained similar results when comparing the PK in eight
patients with falciparum malaria and ten healthy sub-
jects. However, given the relatively small size of both
the Binh et al [9] and Teja-Isavadharm et al [35] stu-
dies, drawing definitive conclusions regarding differences
in PK between healthy and infected subjects is not pos-
sible at present. Nonetheless, as DHA clearance is
dependent upon hepatic blood flow, a reduction in
clearance, and consequently an increase in exposure,
associated with acute infection would be consistent with
DHA’s known pharmacokinetic properties.
Drug-drug interactions
Given the metabolic pathways of AS (esterase-catalyzed
hydrolysis) and DHA (UGT-mediated conjugation), AS
should not be susceptible to the many common drug-
drug interactions involving CYP450 enzymes. Agents
evaluated for their drug interaction potential with orally
administered AS include atovaquone-proguanil [56], sul-
phadoxine-pyrimethamine [57], pyronaridine [47],
mefloquine [24], chlorproguanil-dapsone [34], artemisi-
nin [41], and amodiaquine [27]. AS coadministration
does not appear to alter the PK of atovaquone-proguanil
[56] or sulphadoxine-pyrimethamine [57]. No significant
change in DHA AUC was detected when AS was coad-
ministered with mefloquine [24]. In the PopPK analysis
of AS and DHA PK following oral AS administration by
Tan et al (described above), coadministration of AS with
the Mannich-base derivative pyronaridine was not deter-
mined to exert a significant influence on AS or DHA
pharmacokinetics [47]. Multiple dose administration of
AS did not alter the PK of artemisinin; however, artemi-
sinin coadministration with AS in ten healthy adults was
associated with a more thant w o - f o l di n c r e a s ei nD H A
AUC, a finding which led the authors to speculate that
artemisinin may act as a UGT inhibitor [41]. Finally, AS
coadministration with chlorproguanil-dapsone did not
produce significant alterations in chlorproguanil or dap-
sone PK, although moderate increases in exposure to
the metabolites chlorcycloguanil and monoacetyl dap-
sone were detected. No clinically significant alterations
of AS and DHA pharmacokinetics were found to be
associated with AS-chlorproguanil-dapsone combination
therapy [34].
Orrell et al [27] investigated the drug interaction
potential of artesunate and amodiaquine. The authors
conducted a crossover study in which 12 healthy African
adults received 4 mg/kg AS on day 0 and either amodia-
quine or amodiaquine+AS on day 7, with the alternative
regimen administered on day 28. The investigators
determined that when amodiaquine and AS were coad-
ministered, the mean DHA AUC was approximately
33% lower, the mean DHA Cmax was 49% lower, and
the mean DHA half-life was 57% longer than when AS
was administered alone [27]. The AUC of the amodia-
quine metabolite desethylamodiaquine was determined
to be 45% lower when amodiaquine was coadministered
with AS. However, the subject with the highest desethy-
lamodiaquine AUC during amodiaquine+AS coadminis-
tration was excluded from the amodiaquine drug
interaction analysis [27]. Orrell et al do not speculate
on the source of the interaction. Given the small size of
the study, and the lack of any clear physiologic basis for
the observed interaction, further study would be needed
to fully characterize this potential drug-drug interaction.
Conclusion
AS is a clinically versatile artemisinin derivative utilized
for the treatment of mild to severe malaria infection.
Given the therapeutic significance of AS, and the neces-
sity of appropriate AS dosing, substantial research has
been performed investigating the pharmacokinetics of
AS and its active metabolite DHA. The results of the
studies identified in this review indicate that administra-
tion of IV AS produces an AS Cmax of substantially
greater magnitude than observed with any other route
of administration. Following IV administration, AS
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concentrations within 25 minutes post-dose. AS and
DHA display average clearance values of 2 - 3 L/kg/hr
and 0.5 - 1.5 L/kg/hr, respectively, with volume esti-
mates averaging 0.1 - 0.3 L/kg for AS and 0.5 - 1.0 L/kg
for DHA. IM administration of AS is associated with
high bioavailability, as assessed by DHA exposure.
Although generally displaying similar PK to IV AS, IM
AS does produce lower Cmax, higher V/F, and longer
half-life values for AS, as well as longer Tmax values for
DHA, than IV administration.
Following oral AS administration, peak AS concentra-
tions are attained within an hour, with AS eliminated
with a half-life of 20 - 45 minutes. DHA Cmax values
occur within two hours post-dose; DHA half-life values
average 0.5 - 1.5 hours. A marked discrepancy in AS
and DHA AUC values is apparent following oral AS
administration, with DHA AUC values commonly deter-
mined to be more than 10-fold higher than correspond-
ing AS AUC values. The PK parameters obtained in
studies with rectal AS administration are generally simi-
lar to those obtained in studies with oral administration,
although AS Tmax is delayed and AS half-life extended.
PopPK analyses of AS/DHA data following oral and rec-
tal AS administration suggest that weight and pregnancy
represent influential predictors of DHA pharmacoki-
netics following AS administration.
To date, drug interactions studies of AS with various
other anti-malarial agents have not yielded strong evi-
dence of clinically relevant drug-drug interactions invol-
ving AS. Several relatively small studies examining the
effects of infection on AS and DHA PK indicate that
acute malaria infection may be associated with PK
changes; however, determining the exact nature of such
changes will require further study. Similarly, present evi-
dence suggests that pregnancy may result in PK changes
which will require further study for full elucidation.
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